Changing Market Dynamics in Rheumatoid Arthritis.
Analyst Christina Vasiliou talks you through the changing market dynamics in rheumatoid arthritis
By Christina Vasiliou, Senior Analyst
7 April 2015
I joined Datamonitor Healthcare in early 2014, having completed an MPhil in Bioscience Enterprise at the University of C...
Read full bio
The rheumatoid arthritis (RA) market, worth in excess of $17bn in the US, Japan and five major EU markets in 2014, will continue to expand over the next 10 years. While the marketed anti-TNF biologics have demonstrated strong efficacy in RA and are expected to continue to dominate the early line setting, a significant unmet need remains for novel agents suitable for patients refractory to TNF-inhibition. As a result, strong investments continue in RA. With our webinar, you’ll be able to identify where market opportunities exist within the RA space.
On Thursday 23rd April, Christina Vasiliou evaluated Datamonitor Healthcare’s patient-based forecast of key marketed and pipeline brands for the treatment of RA. This webinar will identify and discuss the key treatment trends in RA and will examine the dynamics that will contribute to the market’s growth.
Key questions answered:
- How will emerging interleukin antagonists perform compared to the established anti-TNF biologics?
- How will novel oral small molecules impact the RA treatment algorithm?
- What role will biosimilars versions of branded anti-TNF agents play in the RA market?
Posted in Immunology and Inflammation.